الفهرس 
Table of ContentsOnly 14 pages are availabe for public view
 |  | from | 147 |  |  |
| | | from | 147 | | |
Abstract
Novel flow diversion therapies on the horizon are an evolving brainstorm of multifaceted strategies to modify the treatment of cerebrovascular pathologies, generating new therapeutic options for the endovascular community. Modifications of flow diversion are currently being tested in some cardiovascular trials with elegant, bio-resorbable stent scaffoldings (Kang et al., 2021). There is a continued necessity for improving navigability and easeof- use of FDDs. The second generation FDDs are definitely a welcome advance, however larger sizes remain stiff and could be difficult to navigate in tortuous anatomy. In addition, using the FDD from the advancer wire could still be relatively hard (Ten Brinck et al., 2020). We deigned our study to assess and evaluate the efficacy of FDs in the obliteration and treatment of IAs. This study was done in Miami university and other 11 participating centers across the united states which were assigned in the STARR data multi-centric study. It is an observational, prospective, multi-centric, single arm study. 400 patients participated in this study. Patients between 20 and 80 years were selected regardless the sex with GCS more than or equal 8, with aneurysms more than 1 cm in diameter (giant aneurysms). A complete history were obtained. Patients were assessed clinically via MRS, GCS, motor power, vital signs and neurological examination. Imaging studies of these patients were revised and recorded. Endovascular flow diverting stenting of intracranial aneurysms were done using pipeline embolization device (PED). Some cases received adjuvant